肌肉减少症和心力衰竭中的虚弱：是否存在生物标志物特征？
Sarcopenia and Frailty in Heart Failure: Is There a Biomarker Signature?
机构信息
Department of Cardiology and Pneumology, University of Göttingen Medical Center, Robert-Koch-Str. 40, 37075, Gottingen, Germany.
Heart Institute (InCor), University of São Paulo Medical School, Sao Paulo, SP, Brazil.
出版信息
Curr Heart Fail Rep. 2022 Dec;19(6):400-411. doi: 10.1007/s11897-022-00575-w. Epub 2022 Oct 20.
PURPOSE OF REVIEW
Sarcopenia and frailty are common in patients with heart failure (HF) and are strongly associated with prognosis. This review aims to examine promising biomarkers that can guide physicians in identifying sarcopenia and frailty in HF.
RECENT FINDINGS
Traditional biomarkers including C-reactive protein, aminotransaminase, myostatin, and urinary creatinine as well as novel biomarkers including microRNAs, suppression of tumorigenicity 2 (ST2), galectin-3, and procollagen type III N-terminal peptide may help in predicting the development of sarcopenia and frailty in HF patients. Among those biomarkers, aminotransferase, urinary creatinine, and ST2 predicted the prognosis in HF patients with sarcopenia and frailty. This review outlines the current knowledge of biomarkers that are considered promising for diagnosing sarcopenia and frailty in HF. The listed biomarkers might support the diagnosis, prognosis, and therapeutic decisions for sarcopenia and frailty in HF patients.
目的综述
肌肉减少症和衰弱在心力衰竭（HF）患者中很常见，并且与预后密切相关。本综述旨在探讨有前途的生物标志物，以帮助医生识别 HF 中的肌肉减少症和衰弱。
最近的发现
传统的生物标志物包括 C 反应蛋白、氨基转移酶、肌肉生长抑制素、尿肌酐以及新型生物标志物包括 microRNAs、肿瘤抑制因子 2（ST2）、半乳糖凝集素-3 和 III 型前胶原 N 端肽，可能有助于预测 HF 患者肌肉减少症和衰弱的发展。在这些生物标志物中，氨基转移酶、尿肌酐和 ST2 预测了伴有肌肉减少症和衰弱的 HF 患者的预后。本综述概述了目前认为有希望用于诊断 HF 中肌肉减少症和衰弱的生物标志物的相关知识。列出的生物标志物可能支持 HF 患者肌肉减少症和衰弱的诊断、预后和治疗决策。
Zotero 插件